Skip to main content

Table 1 Alzheimer’s Disease Neuroimaging Initiative 1 subjects included in the study

From: Low levels of cerebrospinal fluid complement 3 and factor H predict faster cognitive decline in mild cognitive impairment

 

Controls

MCI subjects

AD subjects

P value

Number of participants

    

 All

(n = 110)

(n = 187)

(n = 92)

 

 Hgb ≤ 1,500 ng/ml

(n = 96)

(n = 163)

(n = 83)

 

Age at baseline (years)a

    

 All

75.4 (5.2)

74.0 (7.6)

74.4 (7.7)

0.24

 Hgb ≤ 1,500 ng/ml

75.6 (5.0)

74.5 (7.6)

74.8 (7.9)

0.42

Gender (% female)b

    

 All

49.1

33.2

43.8

0.019

 Hgb ≤ 1,500 ng/ml

46.9

33.7

47.0

0.046

Education (years)a

    

 All

15.7 (2.8)

15.8 (3.0)

15.0 (3.2)

0.15

 Hgb ≤ 1,500 ng/ml

15.8 (2.8)

15.8 (3.0)

15.1 (3.2)

0.19

MMSEa

    

 All

29.1 (1.0)

27.0 (1.8)

23.6 (1.9)

<0.0001

 Hgb ≤ 1,500 ng/ml

29.1 (1.0)

27.0 (1.8)

23.7 (1.9)

<0.0001

ADAS-Coga

    

 All

9.7 (4.2)

18.6 (6.7)

28.5 (8.5)

<0.0001

 Hgb ≤ 1,500 ng/ml

9.9 (4.1)

18.7 (6.2)

28.7 (7.7)

<0.0001

APOE ϵ4 presence (%)b

    

 All

24.5

54.0

70.7

<0.0001

 Hgb ≤ 1,500 ng/ml

24.0

55.2

68.7

<0.0001

Hgb (ng/ml)c

    

 All

42.4 (0.0 to 418.8)

24.9 (0.0 to 477.7)

87.5 (0.0 to 338.4)

0.79

 Hgb ≤ 1,500 ng/ml

19.6 (0.0 to 171.0)

0.64 (0.0 to 195.4)

42.9 (0.0 to 226.1)

0.40

Factor H (ng/ml)c

    

 All

1463.5 (1132.1 to 1954.1)

1478.9 (1177.6 to 2005.5)

1660.5 (1171.4 to 2274.1)

0.26

 Hgb ≤ 1,500 ng/ml

1445.4 (1128.8 to 1877.1)

1452.0 (1176.3 to 1928.3)

1507.9 (1145.3 to 2053.2)

0.46

Complement 3 (ng/ml)c

    

 All

3331.4 (2595.5 to 4743.4)

3696.0 (2658.9 to 4905.2)

3894.6 (2567.6 to 5466.0)

0.40

 Hgb ≤ 1,500 ng/ml

3331.4 (2644.1 to 4819.2)

3614.1 (2559.7 to 4597.7)

3690.3 (2522.3 to 5328.1)

0.73

Complement 3/factor Hc

    

 All

2.40 (1.80 to 2.91)

2.42 (2.01 to 2.84)

2.20 (1.95 to 2.64)

0.31

 Hgb ≤ 1,500 ng/ml

2.41 (1.86 to 2.95)

2.41 (1.98 to 2.82)

2.26 (1.95 to 2.78)

0.55

Aβ1–42 (pg/ml)c

    

 All

220.0 (159.0 to 253.0)

146.0 (128.0 to 202.0)

136.0 (120.8 to 160.5)

<0.0001

 Hgb ≤ 1,500 ng/ml

220.0 (159.5 to 252.5)

146.0 (128.0 to 210.3)

137.0 (121.5 to 161.5)

<0.0001

Total tau (pg/ml)c

    

 All

61.0 (48.0 to 86.0)

87.0 (65.0 to 122.0)

110.5 (81.0 to 153.0)

<0.0001

 Hgb ≤ 1,500 ng/ml

61.0 (48.0 to 79.5)

88.0 (65.0 to 126.0)

109.0 (77.0 to 143.0)

<0.0001

p-tau181 (pg/ml)c

    

 All

20.0 (16.0 to 29.0)

31.5 (21.0 to 45.0)

36.0 (29.0 to 49.0)

<0.0001

 Hgb ≤ 1,500 ng/ml

19.0 (15.0 to 26.5)

31.0 (20.5 to 45.0)

35.0 (28.0 to 46.5)

<0.0001

  1. Aβ1–42, amyloid β peptide 1–42; AD, Alzheimer’s disease; ADAS-Cog, Alzheimer’s disease Assessment Scale – cognitive subscale; APOE ϵ4, apolipoprotein E epsilon 4 allele; Hgb, hemoglobin; MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination; p-tau181, tau phosphorylated at threonine 181. aMean (standard deviation), P value obtained using analysis of variance. bP value obtained using the chi-square test. cMedian (first quartile to third quartile), P value obtained using the Kruskall–Wallis test.